External
Global pharmaceutical policy changes are creating new challenges for biotech companies seeking to protect asset value and plan international launches. Developments such as US Most-Favored-Nation (MFN) pricing and Europe's Joint Clinical Assessment (JCA) are adding uncertainty to investment decisions, licensing negotiations and launch planning.
Join Simon-Kucher experts on 2 December 2026, 14:00–15:00 GMT, for a webinar examining the implications of these policy developments for biotech dealmaking and global launches.
The session will explore how policy uncertainty could influence investor expectations, asset valuation and partnership decisions. Experts will also discuss key considerations for international launch sequencing and market access, with a focus on anticipating policy risks and strengthening biotech companies' position in discussions with investors and potential partners.
